PANDEMIC - CBDC -FREEDOM - TRUTH

EUROPEAN PARLAMENT INTERNATIONAL COVID SUMMIT 3 “You Cannot Comply Your Way Out of Tyranny”: The Explosive Speech That Shook the European Parliament What happened inside the European Parliament during this international summit was not routine politics. It was not diplomatic language. And it was certainly not business as usual. What you are about to watch — and what this post introduces — is a raw, uncompromising denunciation of how the COVID era was handled, framed not as a public health response, but as a global experiment in control, compliance, and psychological warfare . A Historic Summit — And a Breaking Point Held inside one of the most important institutional venues in Europe, this conference brought together members of the global scientific, medical, and legal community. From the outset, it was described as unique and historic — not only for the quality of its speakers, but for the gravity of the issues addressed. Very quickly, however, the tone shifted from forma...

CTS e AstraZeneca: decisioni tra politica, pressione mediatica e scienza ignorata VIDEO: https://rumble.com/v6xyz74-cts-video-di-una-riunione.-desecretato.html?mref=3dpqxo&mc=74zqc ▶ Guarda il video su Rumble Verbale completo: Scarica il VERBALE CTS (PDF) Executive Summary – Riunione CTS 09/06/2021 Durata: 2h 15m Partecipanti chiave: Franco Locatelli (Presidente CTS) Roberto Speranza (Ministro della Salute) Gen. Francesco Paolo Figliuolo (Commissario Straordinario) Nicola Magrini (DG AIFA) Giorgio Palù, Gianni Rezza, Silvio Brusaferro Fabio Ciciliano, Donato Greco, Cinzia Caporale, Alessia Melegaro, Sergio Abrignani Obiettivi della riunione Rivalutare le raccomandazioni sull’uso di AstraZeneca alla luce del calo della circolazione virale. Definire la strategia per la seconda dose: mantenere AstraZeneca o passare a vaccini a mRNA (eterologa). Stabilire una linea di comunicazione univoca p...

 Pregnant Women Not to Receive COVID Shots STORY AT-A-GLANCE In February 2021, Pfizer launched a randomized, placebo-controlled, observer-blind study to evaluate the safety of its COVID-19 shot — BNT162b2 — in healthy pregnant women The injections were set to take place between 24 and 34 weeks’ gestation, with participants randomized 1-to-1 to receive a COVID-19 shot or placebo The study was initially set to enroll 4,000 women, but Pfizer only signed up 349, then stopped enrollment entirely The CDC’s widespread endorsement of COVID-19 shots for pregnant women before the study was completed may have negated the need for the trial Pfizer stated that because so many pregnant women had already gone ahead and gotten the shot, due to the government’s endorsement, enrollment dropped and there was no reason to move ahead with the study No randomized trial data are available for use of the COVID-19 shot in pregnant women, and Pfizer cut its pregnancy trial short. 1  But this doesn’t st...

Acute Myocarditis Following COVID-19 mRNA Vaccination in Adults Aged 18 Years or Older   Results Of 2 392 924 KPSC members who received at least 1 dose of COVID-19 mRNA vaccines, 50.2% received mRNA-1273 and 50.0% BNT162b2. In this cohort, 54.0% were women, 31.2% White, 6.7% Black, 37.8% Hispanic, and 14.3% were Asian individuals. Median age was 49 years (IQR, 34-64 years), 35.7% were younger than 40 years, and 93.5% completed 2 doses of vaccines. In the unexposed group of 1 577 741 individuals, median (IQR) age was 39 (28-53) years, 53.7% were younger than 40 years, 49.1% women, 29.7% White, 8.8% Black, 39.2% Hispanic, and 6.6% were Asian individuals. There were 15 cases of confirmed myocarditis in the vaccinated group (2 after the first dose and 13 after the second), for an observed incidence of 0.8 cases per 1 million first doses and 5.8 cases per 1 million second doses over a 10-day observation window ( Table 1 ). All were men, with a median (IQR) age of 25 (20-32) years. Among...